SCHEMBL10126075

SCHEMBL10126075

Cc1ccc(-c2cc3nc(-c4ccc(-c5ccc(-c6nc7ccccc7o6)cc5)cc4)c(-c4ccc(-c5ccc(-c6nc7ccccc7o6)cc5)cc4)nc3cc2-c2ccc(C)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 0.55
RAB9A P51151 12/20 0.55
KDM4E B2RXH2 8/20 0.55
SMN1; SMN2 Q16637 8/20 0.55
HPGD P15428 7/20 0.55
ALDH1A1 P00352 7/20 0.55
HSD17B10 Q99714 5/20 0.55
TP53 P04637 3/20 0.55
CASP3 P42574 2/20 0.52
SENP8 Q96LD8 2/20 0.52
SENP7 Q9BQF6 2/20 0.52
SENP6 Q9GZR1 2/20 0.52
POLB P06746 1/20 0.52
PTPN2 P17706 2/20 0.52
PTPN1 P18031 2/20 0.52
PTPN5 P54829 2/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ATM Q13315 1/20 0.51
MAPT P10636 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10125945 0.97 NPC1 (0.57) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10126061 0.91 NPC1 (0.54) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10126093 0.91 NPC1 (0.55) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10126084 0.91 NPC1 (0.55) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10125952 0.91 NPC1 (0.55) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10125963 0.91 NPC1 (0.55) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10125924 0.90 TDP1 (0.60) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10315434 0.90 NPC1 (0.48) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10125938 0.89 NPC1 (0.52) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10315196 0.89 NPC1 (0.50) NPC1RAB9AKDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 NPC1 4763/4885RAB9A 1141/4885KDM4E 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.